Table 1: DSM-V Schizophrenia Specifiers
Table 2: Classification of Schizophrenia According to DSM-IV and ICD-10
Table 3: Other Schizophrenia Spectrum Disorders, 2015
Table 4: Symptoms of Schizophrenia
Table 5: Treatment Guidelines for Schizophrenia
Table 6: Most Prescribed Drugs for Schizophrenia in the 7MM, 2015
Table 7: Country Profile – 5EU
Table 8: Leading Treatments for Schizophrenia, 2015
Table 9: Product Profile – Abilify
Table 10: Efficacy Results for Abilify in Schizophrenia Trials
Table 11: Efficacy Results for Abilify in Schizophrenia Trials
Table 12: AEs at =2% Incidence in Schizophrenia and Bipolar I Disorder Trials of Abilify
Table 13: AEs at =2% Incidence in a Schizophrenia Trial of Abilify Maintena
Table 14: Abilify SWOT Analysis, 2016
Table 15: Product Profile – Aristada
Table 16: Efficacy Results for Aristada in Schizophrenia Trial
Table 17: AEs at =2% Incidence in a Schizophrenia Trial of Aristada
Table 18: Aristada SWOT Analysis, 2016
Table 19: Product Profile – Clozapine
Table 20: Efficacy Results for Clozapine in Treatment-Resistant Schizophrenia Patients
Table 21: AEs at =5% Incidence in a Short-Term Trial of Clozapine
Table 22: AEs at =2% Incidence in All Clinical Trials of Clozapine (Excluding InterSePT)
Table 23: AEs at =10% Incidence During the InterSePT Trial of Clozapine
Table 24: Clozapine SWOT Analysis, 2016
Table 25: Product Profile – Fanapt
Table 26: AEs at =2% Incidence in Short-Term Trials of Fanapt
Table 27: Fanapt SWOT Analysis, 2016
Table 28: Product Profile – Geodon
Table 29: AEs at =2% Incidence in Schizophrenia Trials of Geodon
Table 30: Geodon SWOT Analysis, 2016
Table 31: Product Profile – Invega
Table 32: Efficacy of Invega Sustenna in Adult Schizophrenia Short-Term Trials
Table 33: AEs at =2% Incidence in Adult Schizophrenia Trials of Invega
Table 34: AEs at =2% Incidence in an Adolescent Schizophrenia Trial of Invega
Table 35: AEs at =2% Incidence in Schizophrenia Trials of Invega Sustenna
Table 36: AEs at =2% Incidence in a Long-Term Maintenance Trial of Invega Trinza in Schizophrenic Patients
Table 37: Invega SWOT Analysis, 2016
Table 38: Product Profile – Latuda
Table 39: Efficacy Results for Latuda in Schizophrenia Trials
Table 40: AEs at =2% Incidence in Schizophrenia Trials of Latuda
Table 41: Latuda SWOT Analysis, 2016
Table 42: Product Profile – Lonasen
Table 43: Efficacy Results for Lonasen in Haloperidol-Controlled Clinical Trial
Table 44: Efficacy Results for Lonasen in Risperidone-Controlled Clinical Trial
Table 45: AEs at =5% Incidence in a Short-Term Trial of Lonasen
Table 46: Lonasen SWOT Analysis, 2016
Table 47: Product Profile – Rexulti
Table 48: Efficacy Results for Rexulti in Short-Term Schizophrenia Trials
Table 49: AEs at =2% Incidence in Schizophrenia Trials of Rexulti
Table 50: Rexulti SWOT Analysis, 2016
Table 51: Product Profile – Risperdal
Table 52: Efficacy Results for Risperdal Consta in a 12-Week Schizophrenia Study
Table 53: AEs at =2% Incidence in Adult Schizophrenia Trials of Risperdal
Table 54: AEs at =5% Incidence in a Pediatric Schizophrenia Trial of Risperdal
Table 55: AEs at =5% Incidence in an Adult Schizophrenia Trial of Risperdal Consta
Table 56: Risperdal SWOT Analysis, 2016
Table 57: Product Profile – Saphris
Table 58: Efficacy Results for Saphris in Short-Term Schizophrenia Trials
Table 59: AEs at =2% Incidence in Schizophrenia Trials of Saphris
Table 60: Saphris SWOT Analysis, 2016
Table 61: Product Profile – Seroquel
Table 62: Efficacy Results for Seroquel in a Six-Week Schizophrenia Study
Table 63: Efficacy Results for Seroquel in Short-Term Schizophrenia Studies
Table 64: Efficacy Results for Seroquel XR in Schizophrenia Trials
Table 65: AEs at =2% Incidence in Adult Schizophrenia and Bipolar Mania Trials of Seroquel
Table 66: AEs at =2% Incidence in a Short-Term Trial of Seroquel in Schizophrenic Adolescents
Table 67: AEs at =2% Incidence in Six-Week Trials of Seroquel XR in Schizophrenic Adults
Table 68: Seroquel SWOT Analysis, 2016
Table 69: Product Profile – Vraylar
Table 70: Efficacy Results for Vraylar in a Six-Week Schizophrenia Study
Table 71: Efficacy Results for Vraylar in Short-Term Schizophrenia Studies
Table 72: AEs at =2% Incidence in Short-Term Schizophrenia Trials of Vraylar
Table 73: Vraylar SWOT Analysis, 2016
Table 74: Product Profile – Zyprexa
Table 75: AEs at =5% Incidence in Adult Schizophrenia Trials of Zyprexa
Table 76: AEs at =2% Incidence in Short-Term Trials of Zyprexa
Table 77: AEs at =1% Incidence in Adult Schizophrenia Trials of Zyprexa IntraMusular
Table 78: AEs at =5% Incidence in Adolescent Schizophrenia Trials of Zyprexa
Table 79: AEs Reported at =2% Incidence in a Schizophrenia Trial of Zyprexa Relprevv
Table 80: Zyprexa SWOT Analysis, 2016
Table 81: Typical antipsychotics SWOT Analysis, 2016
Table 82: Product Profile – Adasuve
Table 83: Efficacy Results for Adasuve in Agitation Trial of Schizophrenia Patients
Table 84: Decrease in FEV1 in Pulmonary Safety Trials of Adasuve
Table 85: Adasuve SWOT Analysis, 2016
Table 86: Summary of Minor Therapeutic Classes, 2015
Table 87: Unmet Need and Opportunity in Schizophrenia
Table 88: Product Profile – ALKS-3831
Table 89: ALKS-3831 SWOT Analysis, 2016
Table 90: Product Profile – ITI-007
Table 91: Efficacy Results for ITI-007 in a Phase II Schizophrenia Trial
Table 92: Key Safety Data From a Phase II in a Schizophrenia Trial of ITI-007
Table 93: ITI-007 SWOT Analysis, 2016
Table 94: Product Profile – Lu AF35700
Table 95: Lu AF35700 SWOT Analysis, 2016
Table 96: Product Profile – MIN-101
Table 97: Efficacy Results for MIN-101 in a 12-Week Phase IIb Schizophrenia Study
Table 98: Safety Evaluation of MIN-101 Phase IIa Clinical Trial in Schizophrenia
Table 99: AEs at =5% Incidence in a Phase IIb Schizophrenia Trial of MIN-101
Table 100: Safety Evaluation of MIN-101 Phase IIb Clinical Trial in Schizophrenia
Table 101: MIN-101 SWOT Analysis, 2016
Table 102: Product Profile – Risperidone Implant
Table 103: Risperidone Implant SWOT Analysis, 2016
Table 104: Product Profile – Risperidone ISM
Table 105: Risperidone ISM SWOT Analysis, 2016
Table 106: Product Profile – RBP-7000
Table 107: Efficacy Results for RBP-7000 in a Phase III Schizophrenia Trial
Table 108: AEs reported in a Phase III Schizophrenia Trial of RBP-7000A
Table 109: RBP-7000 SWOT Analysis, 2016
Table 110: Product Profile – AVN-211
Table 111: Attention tests and measures evaluated in a Phase IIa Schizophrenia Trial of AVN-211
Table 112: Psychometric Results in a Phase IIa Schizophrenia Trial of AVN-211
Table 113: Results of the Attention Measures that Showed Significant Changes in a Phase IIa Schizophrenia Trial of AVN-211
Table 114: AVN-211 SWOT Analysis, 2016
Table 115: Product Profile – NaBen
Table 116: PANSS Clinical Measures During the Phase II Trial of Sodium Benzoate Adjunctive Therapy in Schizophrenia
Table 117: Other Clinical Measures During the Phase II Trial of Sodium Benzoate Adjunctive Therapy in Schizophrenia
Table 118: Cognitive Measures During the Phase II Trial of Sodium Benzoate Adjunctive Therapy in Schizophrenia
Table 119: NaBen SWOT Analysis, 2016
Table 120: Drugs in Development for Schizophrenia, 2015
Table 121: Key Events Impacting Sales for Schizophrenia in the 5EU, 2015–2025
Table 122: Schizophrenia Market in the 5EU – Drivers and Barriers, 2015–2025
Table 123: Key Launch Dates
Table 124: Key Patent/Exclusivity Expiries
Table 125: High-Prescribing Psychiatrists (Non-KOLs) Surveyed, By Country